APDN - アプライドDNAサイエンシス （Applied DNA Sciences Inc） アプライドDNAサイエンシスAPDNのチャート
APDNの企業情報
| symbol | APDN |
|---|---|
| 会社名 | Applied DNA Sciences Inc （アプライドDNAサイエンシス） |
| 分野（sector） | Consumer Services 消費者サービス |
| 産業（industry） | Other Consumer Services |
| 業種 | 化学_特殊化学製品 工業（Industrials） |
| 概要 | 事業概要 Applied DNA Sciences Inc. is engaged in creating security solutions addressing the challenges of modern commerce. The Company is also engaged in the large-scale production of specific deoxyribonucleic acid (DNA) sequences using the polymerase chain reaction (PCR). Its principal technology platform includes SigNature DNA SigNature T DNA fiberTyping DNAnet digitalDNA SigNify and Beacon. Its SigNify IF portable DNA reader provides definitive real-time authentication of SigNature DNA in the field-DNA becomes a solution for supply chain integrity. SigNature DNA is the Company''s platform ingredient at the core of all its security solutions. It provides forensic power and protection for a range of applications. SigNature T DNA is a tagging and authentication system specifically designed for textiles and apparel. DNAnet is a DNA marker that can be used to definitively link evidence and offenders to specific crime scenes and help return stolen or lost property to its rightful owner. アプライドDNAサイエンシスは、米国のDNAセキュリティ―ソリュ―ション会社。製品、ブランド、知的財産権の偽造や転用を防ぐため、北米と欧州で、DNAタグを利用した偽造防止技術を供給する。主な製品は、｢SigNatureDNA｣、｢fiberTyping｣、｢ DNANet｣、 ｢digitalDNA｣など。本社は、ニューヨーク州スト―ニ―ブルック。 Applied DNA is commercializing LinearDNA™, its proprietary, large-scale polymerase chain reaction ('PCR')-based manufacturing platform that allows for the large-scale production of specific DNA sequences. The LinearDNA platform has utility in the nucleic acid-based in vitro diagnostics and preclinical nucleic acid-based drug development and manufacturing market. The platform is used to manufacture DNA for customers as components of in vitro diagnostic tests and for preclinical nucleic acid-based drug development in the fields of adoptive cell therapies (CAR T and TCR therapies), DNA vaccines (anti-viral and cancer), RNA therapies, clustered regularly interspaced short palindromic repeats (CRISPR) based therapies, and gene therapies. Applied DNA has also established a COVID-19 diagnostic and testing offering that is in the early stages of commercialization and is grounded in the Company's deep expertise in DNA. The LinearDNA platform also has non-biologic applications, such as supply chain security, anti-counterfeiting and anti-theft technology. Key end-markets include textiles, pharmaceuticals and nutraceuticals, and cannabis, among others. |
| 本社所在地 | 50 Health Sciences Drive Stony Brook NY 11790 USA |
| 代表者氏名 | James A. Hayward ジェームズ・A・ヘイワード |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +1 631-240-8800 |
| 設立年月日 | 1983年 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 60人 |
| url | www.adnas.com |
| nasdaq_url | https://www.nasdaq.com/symbol/apdn |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -10.19729 |
| 終値（lastsale） | 1.42 |
| 時価総額（marketcap） | 42759120.94 |
| 時価総額 | 時価総額（百万ドル） 43.36136 |
| 売上高 | 売上高（百万ドル） 3.85349 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 40.84654 |
| 当期純利益 | 当期純利益（百万ドル） -11.07232 |
| 決算概要 | 決算概要 BRIEF: For the nine months ended 30 June 2018 Applied DNA Sciences Inc revenues decreased 25% to $2.7M. Net loss decreased 18% to $8.2M. Revenues reflect United States (Country) segment decrease of 58% to $1.1M Europe segment decrease of 17% to $799K. Lower net loss reflects Selling general and administrative decrease of 29% to $7.5M (expense) Depreciation and amortization decrease of 13% to $426K (expense). |
APDNのテクニカル分析
APDNのニュース
Applied DNA Sciences files a $75 million mixed securities shelf 2023/05/30 20:11:01 Investing.com
https://www.investing.com/news/assorted/applied-dna-sciences-files-a-75-million-mixed-securities-shelf-432SI-3094194
Applied DNA Sciences, Inc. 2023 Q2 - Results - Earnings Call Presentation 2023/05/12 02:54:50 Seeking Alpha
The following slide deck was published by Applied DNA Sciences, Inc.
Applied DNA Sciences, Inc. (APDN) Q2 2023 Earnings Call Transcript 2023/05/12 02:54:08 Seeking Alpha
Applied DNA Sciences, Inc. (NASDAQ:NASDAQ:APDN) Q2 2023 Results Earnings Conference Call May 12, 2023 4:30 PM ETCompany ParticipantsSanjay Hurry - Head of Investor RelationsBeth Jantzen -…
Applied DNA Sciences: Q2 Earnings Insights 2023/05/11 20:50:33 Benzinga
Applied DNA Sciences (NASDAQ: APDN ) reported its Q2 earnings results on Thursday, May 11, 2023 at 04:05 PM. Here''s what investors need to know about the announcement. Earnings Applied DNA Sciences reported in-line EPS of … Full story available on Benzinga.com
Applied DNA Sciences, Inc.: Applied DNA Reports Second Quarter Fiscal 2023 Financial Results and Provides Corporate Update 2023/05/11 20:14:00 Finanz Nachrichten
- linearDNA Gaining Momentum as a Differentiated DNA Template for mRNA Production, Company Identifies Early Development-Stage Acquisition Target to Potentially Expand Commercial Advantages -- Balan…
This stocks will boost Up Your investment: Seelos Therapeutics, Inc. (NASDAQ:SEEL -2.54%), Applied DNA Sciences, Inc. (NASDAQ:APDN) 2023/02/18 11:54:03 Stock Equity
SEEL has seen its SMA50 which is now -16.02%. In looking the SMA 200 we see that the stock has seen a -17.33%. APDN has seen its SMA50 which is … The post This stocks will boost Up Your investment: Seelos Therapeutics, Inc. (NASDAQ:SEEL -2.54%), Applied DNA Sciences, Inc. (NASDAQ:APDN) appeared first on Stocks Equity .
Applied DNA Sciences''s Return On Capital Employed Insights 2023/02/13 14:47:33 Benzinga
Benzinga Pro data, Applied DNA Sciences (NASDAQ: APDN ) reported Q1 sales of $5.26 million. Earnings fell to a loss of $3.84 million, resulting in a 478.47% decrease from last quarter. Applied DNA Sciences collected $3.56 million in revenue during Q4, but reported earnings showed a $664 thousand loss. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and is a … Full story available on Benzinga.com
Applied DNA Announces New York State Award Valued at Up To $1.5 Million to Support Establishment of cGMP linearDNA Production Capacity on Long Island, New York 2023/02/10 14:34:00 Wallstreet:Online
Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced the receipt of an up to $1.5 million award from New York State’s Empire State Development (ESD) agency. The award is provided by ESD under the Excelsior Jobs Program for qualifying net new job creation as refundable employee tax credits claimed over a benefit period of up to
Applied DNA Sciences, Inc. (APDN) Q1 2023 Earnings Call Transcript 2023/02/10 01:59:04 Seeking Alpha
Applied DNA Sciences, Inc. (NASDAQ:NASDAQ:APDN) Q1 2023 Earnings Conference Call February 9, 2023 4:30 PM ETCompany ParticipantsSanjay Hurry - Investor RelationsBeth Jantzen - Chief…
Applied DNA Sciences, Inc. 2023 Q1 - Results - Earnings Call Presentation 2023/02/09 23:13:11 Seeking Alpha
The following slide deck was published by Applied DNA Sciences, Inc.
Applied DNA to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest on March 28th – 30th from 9:00 a.m. - 5:00 p.m. EDT 2022/03/23 16:00:00 Business Wire
STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #LinearDNA--Applied DNA Sciences, Inc. (NASDAQ: APDN), a leader in cell-free, enzymatic DNA production, today announced that CEO Dr. James A. Hayward is invited to present at the 2022 Virtual Growth Conference presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT. Dr. Hayward’s presentation will be available on-demand for the duration of the conference via the sign-up link: Sign up here to access the presentation During th
Applied DNA Sciences gains on U.S. regulatory nod for COVID-19 sample kit 2022/03/09 17:12:18 Seeking Alpha
The shares of life sciences company, Applied DNA Sciences <> are rising on Wednesday amid reports that the U.S
Applied DNA Raises $4.2M Via Registered Direct Offering 2022/02/25 13:12:53 Benzinga
Applied DNA Sciences, Inc. (NASDAQ: APDN ) a polymerase chain reaction based DNA manufacturer , closed its previously announced registered direct offering with an institutional investor of 1.5 million shares of common stock at a price of $2.80 per share for gross proceeds of approximately $4.2 million , before deducting the placement agent’s fees and other offering expenses payable by the company. In a concurrent private placement, Applied DNA also issued to the institutional investor in the offering unregistered … Full story available on Benzinga.com
関連キーワード （化学_特殊化学製品 米国株 アプライドDNAサイエンシス APDN Applied DNA Sciences Inc）
化学産業により作られた製品は、経済の基盤を成し自動車や電機産業のほか、日用雑貨や医薬品など生活の隅々で使用されている。化学産業は経済活動の影響を受ける面が大きく、関連株も景気動向に左右される。化学産業の基礎資材は石油から作られ原油価格の影響も受けやすい。また、日本の化学産業はアジアなど海外企業との競争も激しくなっている。